Evidence map›Paper›PMID 38720365›Full record

ArticleEuropean journal of medical research2024

Human pan-cancer analysis of the predictive biomarker for the CDKN3.

Yingjun Chen, Dai Li, Kaihui Sha, Xuezhong Zhang, Tonggang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yingjun Chen *Department of Infectious Diseases, Binzhou Medical University Hospital, Binzhou, 256600, Shandong, China.
Dai Li *Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
Kaihui ShaBinzhou Medical University School of Nursing, Binzhou, 256600, Shandong, China.
Xuezhong ZhangDepartment of Laboratory Medicine, Zibo Central Hospital, Zibo, 255000, Shandong, China. zhangxuezhong926@126.com.
Tonggang LiuDepartment of Infectious Diseases, Binzhou Medical University Hospital, Binzhou, 256600, Shandong, China. liutonggang123@126.com.

Funding

Natural Science Foundation of Shandong Province No. ZR2020MH322
6 · The paper itself

Abstract

backgroundCell cycle protein-dependent kinase inhibitor protein 3 (CDKN3), as a member of the protein kinase family, has been demonstrated to exhibit oncogenic properties in several tumors. However, there are no pan-carcinogenic analyses for CDKN3.

methodsUsing bioinformatics tools such as The Cancer Genome Atlas (TCGA) and the UCSC Xena database, a comprehensive pan-cancer analysis of CDKN3 was conducted. The inverstigation encompassed the examination of CDKN3 function actoss 33 different kinds of tumors, as well as the exploration of gene expressions, survival prognosis status, clinical significance, DNA methylation, immune infiltration, and associated signal pathways.

resultsCDKN3 was significantly upregulated in most of tumors and correlated with overall survival (OS) of patients. Methylation levels of CDKN3 differed significantly between tumors and normal tissues. In addition, infiltration of CD4 + T cells, cancer-associated fibroblasts, macrophages, and endothelial cells were associated with CDKN3 expression in various tumors. Mechanistically, CDKN3 was associated with P53, PI3K-AKT, cell cycle checkpoints, mitotic spindle checkpoint, and chromosome maintenance.

conclusionOur pan-cancer analysis conducted in the study provides a comprehensive understanding of the involvement of CDKN3 gene in tumorigenesis. The findings suggest that targeting CDKN3 may potentially lead to novel therapeutic strategies for the treatment of tumors.

Indexed as

Biomarkers, TumorCyclin-Dependent Kinase Inhibitor ProteinsNeoplasmsComputational BiologyDNA MethylationDual-Specificity PhosphatasesGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorCDKN3 protein, humanCyclin-Dependent Kinase Inhibitor ProteinsDual-Specificity Phosphatases

Identifiers

PMID38720365
PMCPMC11077798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.